Univest
Univest
  • Markets

Fortis Malar Hospital Share Price Falls 1.02% After Q1 FY27 Results on 4 August 2026

  • August 5, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments

Fortis Malar Hospital share price Rs 49.62 on 4 Aug 2026. Down 1.02%. Q1 FY27 PAT Rs 0 Cr (0.00% YoY). Rev Rs 0 Cr (-95.61% YoY).

The Fortis Malar Hospital share price fell 1.02% to Rs 49.62 on 4 August 2026 as the company reported Q1 FY27 results, with revenue declined -95.61% year on year to Rs 0 Cr from Rs 0 Cr in Q1 FY26 and net profit was flat year on year at Rs 0 Cr. Investors tracking the Fortis Malar Hospital share price reacted to a quarterly report that delivered Rs 0 Cr in consolidated revenue and Rs 0 Cr in net profit for the quarter ended 30 June 2026. The Fortis Malar Hospital share price movement on results day is one of the first data points investors use to gauge market sentiment around the company Q1 FY27 performance, even before studying the underlying financials in detail.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Fortis Malar Hospital Q1 FY27 Results at a Glance
  • Fortis Malar Hospital Share Price Reaction to Q1 FY27 Results
  • Key Business Factors Behind the Fortis Malar Hospital Share Price Move
    • Revenue Performance in Q1 FY27
    • Profitability and Margin Trends
  • What Investors Should Watch in the Fortis Malar Hospital Share Price
  • Conclusion
  • Frequently Asked Questions
    • What happened to the The stock after Q1 FY27 results?
    • What were the Fortis Malar Hospital Q1 FY27 results?
    • What is the The scrip today?
    • Is Fortis Malar Hospital a good buy after Q1 FY27 results?
    • What is the PAT of Fortis Malar Hospital for Q1 FY27?
    • Where can I track the The shares?

Fortis Malar Hospital Q1 FY27 Results at a Glance

The table below summarises the key Q1 FY27 metrics that drove the Fortis Malar Hospital share price reaction on 4 August 2026.

Metric Q1 FY27 (Jun 2026) Q1 FY26 (Jun 2025) YoY Change
Fortis Malar Hospital Q1 FY27 Results on 4 August 2026
Revenue Rs 0 Cr Rs 0 Cr -95.61%
Net Profit (PAT) Rs 0 Cr Rs 0 Cr 0.00%
Gross Margin N/A
Share Price on 4 Aug 2026 Rs 49.62 N/A -1.02% on 4 Aug

Fortis Malar Hospital Share Price Reaction to Q1 FY27 Results

The Fortis Malar Hospital share price move of 1.02% to Rs 49.62 on 4 August 2026 is the market first verdict on the Q1 FY27 numbers. Share price moves on results days are driven by whether the actual figures beat or missed analyst expectations ahead of the announcement. The Fortis Malar Hospital share price reaction should be read alongside the underlying financials: revenue of Rs 0 Cr (-95.61% YoY) and PAT of Rs 0 Cr (0.00% YoY) are the two metrics that will drive analyst estimate revisions for FY27.

Post-result volatility in the Fortis Malar Hospital share price is normal and typically settles over the following sessions as institutional investors complete their position adjustments. Investors who hold the Fortis Malar Hospital share price through earnings should focus on the fundamental trend rather than the single-day price move, which can be amplified by event-driven traders unwinding pre-result positions.

Screen Fortis Malar Hospital and Peers on the Univest Screener

Key Business Factors Behind the Fortis Malar Hospital Share Price Move

Revenue Performance in Q1 FY27

Fortis Malar Hospital reported revenue of Rs 0 Cr for Q1 FY27, declined -95.61% year on year from Rs 0 Cr in Q1 FY26. Revenue trajectory is the starting point for understanding why the Fortis Malar Hospital share price moved the way it did on 4 August 2026. Investors tracking the Fortis Malar Hospital share price should monitor whether this revenue growth rate sustains into Q2 FY27 (September quarter) or represents a seasonal or one-off dynamic that may not repeat.

Profitability and Margin Trends

The PAT of Fortis Malar Hospital for Q1 FY27 was stable to Rs 0 Cr from Rs 0 Cr in Q1 FY26, a change of 0.00% year on year. The gross margin stood at N/A for the quarter. Profitability trends are a key driver of the Fortis Malar Hospital share price over the medium term, as consistent earnings improvement is what typically drives institutional accumulation of a stock. Investors holding the Fortis Malar Hospital share price should track whether this profit trajectory is sustainable into Q2 and Q3 FY27.

What Investors Should Watch in the Fortis Malar Hospital Share Price

Beyond the Q1 FY27 results, several factors will influence the Fortis Malar Hospital share price trajectory in the coming months. Management commentary on the Q2 FY27 outlook, particularly on demand trends, input cost movements, and any guidance upgrades or downgrades, will be closely watched. The Fortis Malar Hospital share price is also subject to broader market conditions including RBI monetary policy, FII activity, and sector-level sentiment.

For investors evaluating the Fortis Malar Hospital share price at current levels of Rs 49.62, the Q1 FY27 results provide a baseline. The sustainability of the revenue run rate at Rs 0 Cr per quarter and the profit level at Rs 0 Cr will determine whether the Fortis Malar Hospital share price re-rates higher or faces consolidation in subsequent sessions.

Download the Univest iOS App or Univest Android App to track the Fortis Malar Hospital share price and access Q1 FY27 results analysis.

Conclusion

The Fortis Malar Hospital share price fell 1.02% to Rs 49.62 on 4 August 2026 after the company reported Q1 FY27 results showing revenue of Rs 0 Cr (-95.61% YoY) and PAT of Rs 0 Cr (0.00% YoY). The Fortis Malar Hospital share price reaction reflects the market initial assessment of the Q1 FY27 print. Investors should track Q2 FY27 results (due around October 2026) and management guidance for a more complete picture of the FY27 earnings trajectory before making significant decisions based on the Fortis Malar Hospital share price at current levels.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What happened to the The stock after Q1 FY27 results?

Ans. The The shares fell 1.02% to Rs 49.62 on 4 August 2026, reacting to Q1 FY27 results that showed revenue of Rs 0 Cr and PAT of Rs 0 Cr.

What were the Fortis Malar Hospital Q1 FY27 results?

Ans. Fortis Malar Hospital reported revenue of Rs 0 Cr (-95.61% YoY) and PAT of Rs 0 Cr (0.00% YoY) for Q1 FY27 (April to June 2026 quarter) announced on 4 August 2026.

What is the The scrip today?

Ans. The The counter was Rs 49.62 on 4 August 2026, the day Q1 FY27 results were announced. For the latest The company, check NSE (nseindia.com) or the Univest app.

Is Fortis Malar Hospital a good buy after Q1 FY27 results?

Ans. Any decision to buy The stock should be based on your own research and risk profile. Q1 FY27 results show PAT of Rs 0 Cr and revenue of Rs 0 Cr. Consult a SEBI-registered advisor before investing.

What is the PAT of Fortis Malar Hospital for Q1 FY27?

Ans. The PAT (net profit) of Fortis Malar Hospital for Q1 FY27 was Rs 0 Cr, a change of 0.00% year on year from Rs 0 Cr in Q1 FY26.

Where can I track the The shares?

Ans. The The scrip can be tracked on NSE (nseindia.com), BSE (bseindia.com), and the Univest app and screener for live prices, Q1 FY27 results analysis, and investor research.



News
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply